Logo
x

Search

Subscribe Now

Harbour BioMed

Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors

Harbour BioMed Receives the US FDA’s IND Clearance to Initiate P-I Study of HBM9027 for Solid Tumors

  • January 24, 2024
Harbour BioMed to Present Results from P-Ib Study of Porustobart + Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Harbour BioMed to Present Results from P-Ib Study of Porustobart + Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2...

  • May 29, 2023
Harbour BioMed Reports P-III Trial Results of Batoclimab for the Treatment of Generalized Myasthenia Gravis

Harbour BioMed Reports P-III Trial Results of Batoclimab for the Treatment of Generalized Myasthenia Gravis

  • March 6, 2023
Harbour BioMed Receives the US FDA’s IND Clearance of HBM1020 for the Treatment of Advanced Solid Tumors

Harbour BioMed Receives the US FDA’s IND Clearance of HBM1020 for the Treatment of Advanced Solid Tumors

  • January 13, 2023
Harbour BioMed Signs Out-License Agreement with AstraZeneca for HBM7022 to Treat Solid Tumors Using HBICE Platform

Harbour BioMed Signs Out-License Agreement with AstraZeneca for HBM7022 to Treat Solid Tumors Using HBICE Platform

  • April 7, 2022
Insights+: COVID-19 Healthcare News Monthly Updates - December 2020

Insights+: COVID-19 Healthcare News Monthly Updates - December 2020

  • December 31, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.